Skip to content

Treatment of plantar fasciitis - comparison between hyaluronic acid and platelet rich plasma

Ultrasound guided injection of hyaluronic acid versus platelet rich plasma in management of plantar fasciitis refractory to conservative management

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/04/041777
Enrollment
50
Registered
2022-04-11
Start date
Unknown
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M722- Plantar fascial fibromatosis

Interventions

Intervention1: Platelet rich plasma(PRP): PRP is an autologous mixture of highly concentrated platelets and associated growth factors produced by centrifugal separation of whole blood and promotes cel

Sponsors

Department of anaesthesiology and critical careJNMCH AMU ALIGARH
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age > 18 years and 2. Patients of plantar fascitis of atleast 6 weeks duration. 3. Patientâ??s pain refractory to primary conservative treatments (NRS >5). 4. Willingness to participate in the study and forgo any other concomitant treatment modality.

Exclusion criteria

Exclusion criteria: 1. Unwillingness to participate in the study. 2. Arthrosis or arthritis of foot, old-healed tendoachilles rupture. 3. History of foot trauma or Surgery. 4. History of injection in the involved foot during preceding 6 months. 5. Patients with history of vascular insufficiency, neuropathic heel pain, on anti-platelet or anticoagulant therapy, and on aspirin containing NSAIDS. 6. Any foot and ankle deformity including pes planus or pes cavus. 7. Pregnant and Breastfeeding females. 8. Uncontrolled psychiatric disorder or major depression or other severe medical illness. 9. Local infection or ongoing septicaemia. 10. Patients with autoimmune disease, malignancy, uncontrolled diabetes mellitus, hyperlipidemia and patients with BMI >30.

Design outcomes

Primary

MeasureTime frame
1. To determine the degree of pain relief in patients of Plantar Fascitis using Numerical rating scale(NRS)Timepoint: baseline, 1st week, 2nd week, 4th week and 6th week.

Secondary

MeasureTime frame
1. To evaluate the improvement in quality of life using foot health status questionnaire (FHSQ) at baseline and 6 weeks. 2. Requirement of rescue analgesics on weekly basis. 3. Any complication such as pain, bleeding, infection or any other complication occurring during and after the injection shall be noted. Timepoint: baseline, 1 week, 2 week, 4 week, 6 week

Countries

India

Contacts

Public ContactPallavi Agrawal

Jawahar Lal Nehru medical college and hospital, AMU Aligarh

hammadusmani2002@gmail.com9897114190

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026